Advances in the diagnosis, evaluation and management of cholangiocarcinoma
- PMID: 16550045
- DOI: 10.1097/01.mog.0000218967.60633.64
Advances in the diagnosis, evaluation and management of cholangiocarcinoma
Abstract
Purpose of review: Cholangiocarcinoma is an enigmatic malignancy of the biliary tract that has recently been shown to be increasing in incidence globally. There has been recent progress in identifying potential risk factors for the tumor, and in the use of emerging technologies for diagnosis and palliative treatment.
Recent findings: Hepatitis B and C, cirrhosis and alcohol have been described as risk factors for cholangiocarcinoma. A morphology-based classification for cholangiocarcinoma is proposed that will facilitate future descriptive epidemiology, diagnosis and comparative therapeutic studies. Diagnosis may be improved by new approaches to enhance the diagnostic yield and utility of biliary cytology. The role of new imaging approaches such as positron emission tomography scanning, endoscopic ultrasound or optical coherence tomography for diagnosis are being examined and defined. Long-term results for transplantation protocols for curative intent in non-resectable localized disease have been described. Photodynamic therapy looks extremely promising for adjunct therapy of intrahepatic mass lesions.
Summary: Recent advances in the epidemiology, classification, diagnosis and therapy of cholangiocarcinoma are expected to enhance the evaluation and management of patients with this devastating malignancy.
Similar articles
-
Current approaches to the diagnosis and treatment of cholangiocarcinoma.Curr Gastroenterol Rep. 2006 Feb;8(1):30-7. doi: 10.1007/s11894-006-0061-1. Curr Gastroenterol Rep. 2006. PMID: 16510032 Review.
-
Cholangiocarcinoma.Nat Clin Pract Gastroenterol Hepatol. 2006 Jan;3(1):33-42. doi: 10.1038/ncpgasthep0389. Nat Clin Pract Gastroenterol Hepatol. 2006. PMID: 16397610 Review.
-
Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.Cancer. 2016 May 1;122(9):1349-69. doi: 10.1002/cncr.29692. Epub 2016 Jan 22. Cancer. 2016. PMID: 26799932 Review.
-
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.World J Gastroenterol. 2009 Sep 14;15(34):4240-62. doi: 10.3748/wjg.15.4240. World J Gastroenterol. 2009. PMID: 19750567 Free PMC article. Review.
-
[Management of hilar cholangiocarcinoma].J Chir (Paris). 2007 Sep-Oct;144(5):385-92. doi: 10.1016/s0021-7697(07)73992-3. J Chir (Paris). 2007. PMID: 18065892 Review. French.
Cited by
-
Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells.Onco Targets Ther. 2016 Dec 22;10:137-144. doi: 10.2147/OTT.S112364. eCollection 2017. Onco Targets Ther. 2016. PMID: 28053547 Free PMC article.
-
Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.Evid Based Complement Alternat Med. 2013;2013:185158. doi: 10.1155/2013/185158. Epub 2013 Jun 23. Evid Based Complement Alternat Med. 2013. PMID: 23864881 Free PMC article.
-
Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period.J Gastrointest Surg. 2008 Jan;12(1):117-22. doi: 10.1007/s11605-007-0335-4. Epub 2007 Oct 26. J Gastrointest Surg. 2008. PMID: 17963015
-
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.Radiology. 2014 Oct;273(1):30-50. doi: 10.1148/radiol.14132362. Radiology. 2014. PMID: 25247563 Free PMC article. Review.
-
Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia.World J Gastroenterol. 2012 Feb 7;18(5):458-65. doi: 10.3748/wjg.v18.i5.458. World J Gastroenterol. 2012. PMID: 22346252 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials